ARNA

Don’t Buy Orexigen on Diet Pill Hopes

Orexigen Therapeutics joins VIVUS and Arena Pharmaceuticals in an industry that's brought nothing but disappointment to investors: weight-loss drugs. More 

3 Huge Healthcare Trends Can Fatten Your Portfolio

Healthcare concerns in the U.S. are being addressed by companies in the industry. These 3 issues can lead investors to stock opportunities More 

A New Rice Diet Company is Set to Launch Next Month

John Aycoth, a former Washington, D.C., lobbyist, is set to launch his Rice House Healthcare Program next month. More 

GDP, VOD News Lifts Markets: Thursday’s IP Market Recap

Markets moved ahead on solid economic news, setting aside Middle East concerns for at least one session as all 3 indices rose on the day. More 

Arena, Vivus Look Good (And It Has Nothing to Do With the AMA)

The AMA has ruled to classify obesity more intensely -- as a "disease." But are ARNA and VVUS investors justified in being excited? More 

Now That Obesity Is Classified as a ‘Disease’ …

The American Medical Association's decision to classify obesity as a disease will impact physicians, patients, insurers and pharmaceutical companies. More 

New Weight Loss Drug Belviq Finally Available in U.S.

Arena Pharmaceutical's weight-loss drug Belviq will hit the U.S. market this week after being delayed by a Drug Enforcement Administration review. More